tiprankstipranks
Trending News
More News >
Sartorius Stedim Biotech (GB:0RG8)
:0RG8
UK Market
Advertisement

Sartorius Stedim Biotech (0RG8) Share Forecast & Price Target

Compare
1 Followers
See the Price Targets and Ratings of:

0RG8 Analyst Ratings

Strong Buy
8Ratings
Strong Buy
6 Buy
2 Hold
0 Sell
Based on 8 analysts giving stock ratings to
Sartorius
Stedim Biotech
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

0RG8 Stock 12 Month Forecast

Average Price Target

€229.38
▲(35.01% Upside)
Based on 8 Wall Street analysts offering 12 month price targets for Sartorius Stedim Biotech in the last 3 months. The average price target is €229.38 with a high forecast of €245.00 and a low forecast of €210.00. The average price target represents a 35.01% change from the last price of €169.90.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"147":"€147","246":"€246","171.75":"€171.8","196.5":"€196.5","221.25":"€221.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":245,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€245.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":229.38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€229.38</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":210,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€210.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[147,171.75,196.5,221.25,246],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Dec<br/>2024","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,201.1,204.47692307692307,207.85384615384615,211.23076923076923,214.6076923076923,217.98461538461538,221.36153846153846,224.73846153846154,228.1153846153846,231.4923076923077,234.86923076923077,238.24615384615385,241.62307692307692,{"y":245,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,201.1,203.2753846153846,205.45076923076923,207.62615384615384,209.80153846153846,211.97692307692307,214.1523076923077,216.3276923076923,218.50307692307692,220.67846153846153,222.85384615384615,225.02923076923076,227.20461538461538,{"y":229.38,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,201.1,201.7846153846154,202.46923076923076,203.15384615384616,203.83846153846153,204.52307692307693,205.2076923076923,205.8923076923077,206.57692307692307,207.26153846153846,207.94615384615383,208.63076923076923,209.31538461538463,{"y":210,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":202.24,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":181.89,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":148.79,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":184.53,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":172.3,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":186.62,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":179.92,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":186.74,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":223.66,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":184.14,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":206.2,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":188.53,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":201.1,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€245.00Average Price Target€229.38Lowest Price Target€210.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barclays
€250€240
Buy
41.26%
Upside
Reiterated
07/23/25
Barclays Reaffirms Their Buy Rating on Sartorius Stedim Biotech (0RG8)
J.P. Morgan Analyst forecast on GB:0RG8
Richard VosserJ.P. Morgan
J.P. Morgan
€230€225
Buy
32.43%
Upside
Reiterated
07/23/25
Sartorius Stedim Biotech (0RG8) Gets a Buy from J.P. Morgan
RBC Capital Analyst forecast on GB:0RG8
Charles WestonRBC Capital
RBC Capital
€240€230
Buy
35.37%
Upside
Upgraded
07/23/25
Positive Report for Sartorius Stedim Biotech (0RG8) from RBC Capital
Goldman Sachs Analyst forecast on GB:0RG8
James QuigleyGoldman Sachs
Goldman Sachs
€234€232
Buy
36.55%
Upside
Reiterated
07/23/25
Sartorius Stedim Biotech (0RG8) Receives a Buy from Goldman Sachs
Kepler Capital  Analyst forecast on GB:0RG8
Oliver ReinbergKepler Capital
Kepler Capital
€210
Hold
23.60%
Upside
Reiterated
07/22/25
Sartorius Stedim Biotech (0RG8) Receives a Hold from Kepler Capital
UBS
€220
Hold
29.49%
Upside
Reiterated
07/08/25
UBS Sticks to Its Hold Rating for Sartorius Stedim Biotech (0RG8)
Exane BNP Paribas Analyst forecast on GB:0RG8
Odysseas ManesiotisExane BNP Paribas
Exane BNP Paribas
€233
Buy
37.14%
Upside
Initiated
05/29/25
Sartorius Stedim Biotech (0RG8) Receives a New Rating from Exane BNP Paribas
Jefferies Analyst forecast on GB:0RG8
James VaneJefferies
Jefferies
€245
Buy
44.20%
Upside
Reiterated
05/12/25
Analysts' Opinions Are Mixed on These Healthcare Stocks: GlaxoSmithKline (LSE: GB:GSK), Sartorius Stedim Biotech (LSE: GB:0RG8) and Allogene Therapeutics (NASDAQ: ALLO)
Morgan Stanley Analyst forecast on GB:0RG8
Thibault BoutherinMorgan Stanley
Morgan Stanley
€260€250
Buy
47.15%
Upside
Reiterated
04/22/25
Sartorius Stedim Biotech (DIM:FP) (SDMHF) PT Lowered to EUR250 at Morgan StanleyMorgan Stanley analyst Thibault Boutherin lowered the price target on Sartorius Stedim Biotech (DIM:FP) (OTC: SDMHF) to EUR250.00 (from EUR260.00) while maintaining a Overweight rating.
Bernstein
€234
Hold
37.73%
Upside
Reiterated
04/16/25
Sartorius Stedim Biotech (0RG8) Gets a Hold from Bernstein
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barclays
€250€240
Buy
41.26%
Upside
Reiterated
07/23/25
Barclays Reaffirms Their Buy Rating on Sartorius Stedim Biotech (0RG8)
J.P. Morgan Analyst forecast on GB:0RG8
Richard VosserJ.P. Morgan
J.P. Morgan
€230€225
Buy
32.43%
Upside
Reiterated
07/23/25
Sartorius Stedim Biotech (0RG8) Gets a Buy from J.P. Morgan
RBC Capital Analyst forecast on GB:0RG8
Charles WestonRBC Capital
RBC Capital
€240€230
Buy
35.37%
Upside
Upgraded
07/23/25
Positive Report for Sartorius Stedim Biotech (0RG8) from RBC Capital
Goldman Sachs Analyst forecast on GB:0RG8
James QuigleyGoldman Sachs
Goldman Sachs
€234€232
Buy
36.55%
Upside
Reiterated
07/23/25
Sartorius Stedim Biotech (0RG8) Receives a Buy from Goldman Sachs
Kepler Capital  Analyst forecast on GB:0RG8
Oliver ReinbergKepler Capital
Kepler Capital
€210
Hold
23.60%
Upside
Reiterated
07/22/25
Sartorius Stedim Biotech (0RG8) Receives a Hold from Kepler Capital
UBS
€220
Hold
29.49%
Upside
Reiterated
07/08/25
UBS Sticks to Its Hold Rating for Sartorius Stedim Biotech (0RG8)
Exane BNP Paribas Analyst forecast on GB:0RG8
Odysseas ManesiotisExane BNP Paribas
Exane BNP Paribas
€233
Buy
37.14%
Upside
Initiated
05/29/25
Sartorius Stedim Biotech (0RG8) Receives a New Rating from Exane BNP Paribas
Jefferies Analyst forecast on GB:0RG8
James VaneJefferies
Jefferies
€245
Buy
44.20%
Upside
Reiterated
05/12/25
Analysts' Opinions Are Mixed on These Healthcare Stocks: GlaxoSmithKline (LSE: GB:GSK), Sartorius Stedim Biotech (LSE: GB:0RG8) and Allogene Therapeutics (NASDAQ: ALLO)
Morgan Stanley Analyst forecast on GB:0RG8
Thibault BoutherinMorgan Stanley
Morgan Stanley
€260€250
Buy
47.15%
Upside
Reiterated
04/22/25
Sartorius Stedim Biotech (DIM:FP) (SDMHF) PT Lowered to EUR250 at Morgan StanleyMorgan Stanley analyst Thibault Boutherin lowered the price target on Sartorius Stedim Biotech (DIM:FP) (OTC: SDMHF) to EUR250.00 (from EUR260.00) while maintaining a Overweight rating.
Bernstein
€234
Hold
37.73%
Upside
Reiterated
04/16/25
Sartorius Stedim Biotech (0RG8) Gets a Hold from Bernstein
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Sartorius Stedim Biotech

1 Month
xxx
Success Rate
5/8 ratings generated profit
63%
Average Return
+1.25%
initiated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 62.50% of your transactions generating a profit, with an average return of +1.25% per trade.
3 Months
xxx
Success Rate
10/18 ratings generated profit
56%
Average Return
+1.31%
reiterated a xxx
rating 16 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 55.56% of your transactions generating a profit, with an average return of +1.31% per trade.
1 Year
Richard VosserJ.P. Morgan
Success Rate
4/18 ratings generated profit
22%
Average Return
-10.34%
reiterated a buy rating 16 days ago
Copying Richard Vosser's trades and holding each position for 1 Year would result in 22.22% of your transactions generating a profit, with an average return of -10.34% per trade.
2 Years
xxx
Success Rate
1/18 ratings generated profit
6%
Average Return
-19.21%
reiterated a xxx
rating 16 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 5.56% of your transactions generating a profit, with an average return of -19.21% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0RG8 Analyst Recommendation Trends

Rating
Feb 25
Apr 25
May 25
Jun 25
Jul 25
Strong Buy
0
0
0
0
0
Buy
11
16
13
9
7
Hold
4
8
5
8
10
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
15
24
18
17
17
In the current month, 0RG8 has received 7 Buy Ratings, 10 Hold Ratings, and 0 Sell Ratings. 0RG8 average Analyst price target in the past 3 months is 229.38.
Each month's total comprises the sum of three months' worth of ratings.

0RG8 Financial Forecast

0RG8 Earnings Forecast

Next quarter’s earnings estimate for 0RG8 is €0.98 with a range of €0.81 to €1.09. The previous quarter’s EPS was €1.22. 0RG8 beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.03% of the time in the same period. In the last calendar year 0RG8 has Outperformed its overall industry.
Next quarter’s earnings estimate for 0RG8 is €0.98 with a range of €0.81 to €1.09. The previous quarter’s EPS was €1.22. 0RG8 beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.03% of the time in the same period. In the last calendar year 0RG8 has Outperformed its overall industry.

0RG8 Sales Forecast

Next quarter’s sales forecast for 0RG8 is €709.71M with a range of €694.80M to €725.77M. The previous quarter’s sales results were €745.00M. 0RG8 beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.64% of the time in the same period. In the last calendar year 0RG8 has Outperformed its overall industry.
Next quarter’s sales forecast for 0RG8 is €709.71M with a range of €694.80M to €725.77M. The previous quarter’s sales results were €745.00M. 0RG8 beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.64% of the time in the same period. In the last calendar year 0RG8 has Outperformed its overall industry.

0RG8 Stock Forecast FAQ

What is GB:0RG8’s average 12-month price target, according to analysts?
Based on analyst ratings, Sartorius Stedim Biotech’s 12-month average price target is 229.38.
    What is GB:0RG8’s upside potential, based on the analysts’ average price target?
    Sartorius Stedim Biotech has 35.01% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Sartorius Stedim Biotech a Buy, Sell or Hold?
          Sartorius Stedim Biotech has a consensus rating of Strong Buy, which is based on 6 buy ratings, 2 hold ratings and 0 sell ratings.
            What is Sartorius Stedim Biotech’s share price target?
            The average share price target for Sartorius Stedim Biotech is 229.38. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €245.00 ,and the lowest forecast is €210.00. The average share price target represents 35.01% Increase from the current price of €169.9.
              What do analysts say about Sartorius Stedim Biotech?
              Sartorius Stedim Biotech’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.
                How can I buy shares of Sartorius Stedim Biotech?
                To buy shares of GB:0RG8, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis